180 Life Sciences Stock Price, News & Analysis

ATNFW represents the publicly traded warrants of 180 Life Sciences Corp. on the Nasdaq Capital Market. 180 Life Sciences Corp. is described in its public disclosures as a clinical-stage biotechnology company focused on the development of novel drugs that address unmet medical needs in inflammatory diseases, fibrosis and pain. The company is classified under pharmaceutical preparation manufacturing within the broader manufacturing sector.

According to multiple company press releases and SEC filings, 180 Life Sciences concentrates on inflammation as a key driver of disease and is advancing several clinical and pre-clinical programs. The company’s primary development platform is an anti-TNF (tumor necrosis factor) program targeting fibrosis and inflammation, with a lead indication that has been described as being in Phase 2b/3 clinical trials. This work is aimed at conditions where, based on the company’s statements, there are no effective therapies.

Drug development platforms and programs

Public information indicates that 180 Life Sciences has three major drug platforms connected to inflammation, fibrosis and pain. One is an anti-TNF platform focused on fibrosis and inflammatory conditions. Another involves synthetic cannabidiol (CBD) analogs, described as man‑made derivatives of cannabidiol. A third platform is referred to as the α7nAChR program, which targets the alpha 7 nicotinic acetylcholine receptor.

Company communications further describe three clinical programs addressing specific indications: early Dupuytren’s contracture, frozen shoulder, and post‑operative cognitive delirium disorder and dysfunction in elderly patients. In addition, pre‑clinical discovery efforts include oral synthetic cannabidiol analogs for pain related to arthritis, and α7nAChR agonists for inflammatory diseases, initially ulcerative colitis induced after smoking cessation. These programs are presented by the company as part of a broader effort to develop drugs for separate areas of inflammation.

Intellectual property and academic collaborations

180 Life Sciences reports that it is an applicant and licensee of a broad patent portfolio that supports its three major drug platforms in inflammation, fibrosis and pain. A detailed press release describes multiple patent families and issued patents across its anti‑TNF, SCA (synthetic cannabidiol analog) and α7nAChR programs, with coverage in jurisdictions including the United States, Canada, Europe, Australia, Japan and China. The company has highlighted specific patent grants and applications, such as methods of treating frozen shoulder and early stage Dupuytren’s disease, as part of this portfolio.

The company states that its intellectual property estate consists of both its own IP and exclusive worldwide licenses from institutions including Oxford University Innovation Limited, The Kennedy Trust for Rheumatology Research, Stanford University and the Hebrew University. Public materials emphasize that 180 Life Sciences seeks to leverage the combined expertise of scientists and physicians associated with Oxford University, the Hebrew University and Stanford University in designing and advancing its programs.

Corporate history and listing

180 Life Sciences became a standalone publicly traded company through a business combination with KBL Merger Corp IV. A company announcement dated November 10, 2020, reports the completion of this transaction and notes that, following the merger, 180 Life Sciences’ common stock and warrants trade on the Nasdaq Capital Market under the symbols ATNF and ATNFW, respectively. The same disclosure explains that 180 Life Sciences survived as a wholly owned subsidiary of the public entity that assumed the 180 Life Sciences Corp. name.

In a subsequent press release, the company announced that it would ring the Nasdaq opening bell to mark the milestone of becoming a public company. These communications frame the listing as a step to support the advancement of its drug development pipeline in inflammatory diseases, fibrosis and pain.

Strategic focus and capital formation

180 Life Sciences’ news releases describe several private placements and financing activities. For example, in February 2021 the company announced a private placement of common stock and accompanying warrants, with stated gross proceeds to be used for general corporate purposes, working capital, and research and development programs not funded by grants. In a detailed letter to stockholders, the company also notes that many of its clinical studies have been funded through grants and that it has pursued collaborations with academic leaders to conduct clinical development.

Later SEC filings show that the company has engaged in additional equity and debt financings, including large private placements of common stock and pre‑funded warrants, the issuance of strategic advisor warrants, and a senior secured convertible note financing. These filings also describe the launch of a digital asset treasury strategy focused on acquiring Ether (ETH), with related asset management and advisory arrangements. The company has disclosed significant ETH holdings and associated collateral arrangements in connection with its financing activities.

Corporate evolution and name change

In 2025, 180 Life Sciences reported a series of corporate governance and capital structure changes, including amendments to its omnibus incentive plans, adoption of a 2025 option incentive plan, and an increase in authorized common shares. On August 13, 2025, the company filed an 8‑K describing an amendment to its certificate of incorporation to change its name to ETHZilla Corporation, effective August 18, 2025. The same filing states that, at the market open on August 18, 2025, the trading symbol for the company’s common stock on Nasdaq is expected to change from ATNF to ETHZ, and the trading symbol for its public warrants from ATNFW to ETHZW.

Another 8‑K dated August 18, 2025, confirms that the company, now referred to as ETHZilla Corporation, issued a press release announcing the name change from 180 Life Sciences Corp. to ETHZilla Corporation, effective August 18, 2025. These filings indicate that ATNFW represents the historical warrant symbol associated with 180 Life Sciences prior to the transition to the ETHZW symbol.

Business model and sector context

Across its public communications, 180 Life Sciences describes itself as a clinical‑stage biotechnology company that does not yet market approved products but is focused on advancing drug candidates through clinical and pre‑clinical development. The emphasis on anti‑TNF therapies for fibrosis and inflammation, synthetic cannabidiol analogs for pain, and α7nAChR agonists for inflammatory diseases situates the company within the broader biopharmaceutical research and development space. Its classification in pharmaceutical preparation manufacturing reflects its focus on developing pharmaceutical drug candidates, even though it remains in the clinical‑stage category.

Investors reviewing ATNFW as a warrant security should understand that its value is tied to the underlying common stock and the terms of the warrants, as set out in the company’s SEC filings. Those filings, along with the company’s press releases, provide the authoritative source for information on exercise prices, expiration dates, and any adjustments or corporate actions that affect the warrants.